Use of concomitant G-CSF in maintaining efficacious dose and safe delivery of docetaxel in combination with darolutamide in ARASENS: A phase III study

Key Points

• G-CSF administration maintains an efficacious dose of docetaxel with darolutamide, enhancing safety in treatment.
• Participants treated showed a significant improvement in maintaining effective doses, achieving better outcomes without severe side effects.
• This phase III study evaluated the impact of G-CSF in a treatment regimen combining docetaxel and darolutamide for prostate cancer.
• Results suggest the intervention may enable safer delivery of docetaxel, but further validation in larger cohorts is essential.